{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:21:17Z","timestamp":1772166077166,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23H02634"],"award-info":[{"award-number":["23H02634"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP23gm1610013"],"award-info":[{"award-number":["JP23gm1610013"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP23wm0325037"],"award-info":[{"award-number":["JP23wm0325037"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP23wm0325037"],"award-info":[{"award-number":["JP23wm0325037"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["25HA1004"],"award-info":[{"award-number":["25HA1004"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-025-04130-x","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T10:47:22Z","timestamp":1751366842000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical outcomes of flomoxef versus cefmetazole in hospitalized patients with urinary tract infections: combined retrospective analyses of two real-world databases and in vitro data"],"prefix":"10.1186","volume":"23","author":[{"given":"Takahiro","family":"Niimura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuhiro","family":"Goda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiki","family":"Kajihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Yahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aki","family":"Hirabayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Miyata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Ikai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoko","family":"Shinohara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Minato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Ishizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"issue":"2","key":"4130_CR1","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1093\/jac\/dkl483","volume":"59","author":"DM Livermore","year":"2007","unstructured":"Livermore DM, Canton R, Gniadkowski M, Nordmann P, Rossolini GM, Arlet G, et al. CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother. 2007;59(2):165\u201374. https:\/\/doi.org\/10.1093\/jac\/dkl483.","journal-title":"J Antimicrob Chemother"},{"key":"4130_CR2","doi-asserted-by":"publisher","unstructured":"De Champs C, Sirot D, Chanal C, Bonnet R, Sirot J: A 1998 survey of extended-spectrum beta-lactamases in Enterobacteriaceae in France. The French Study Group. Antimicrob Agents Chemother. 2000;44(11):3177\u201379. https:\/\/doi.org\/10.1128\/AAC.44.11.3177-3179.2000. Pubmed: 11036046.","DOI":"10.1128\/AAC.44.11.3177-3179.2000"},{"issue":"2","key":"4130_CR3","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1128\/AAC.50.2.498-504.2006","volume":"50","author":"M Tumbarello","year":"2006","unstructured":"Tumbarello M, Spanu T, Sanguinetti M, Citton R, Montuori E, Leone F, et al. Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob Agents Chemother. 2006;50(2):498\u2013504. https:\/\/doi.org\/10.1128\/AAC.50.2.498-504.2006.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"4130_CR4","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1093\/cid\/cir202","volume":"53","author":"N Gupta","year":"2011","unstructured":"Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis. 2011;53(1):60\u20137. https:\/\/doi.org\/10.1093\/cid\/cir202. Pubmed:21653305.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"4130_CR5","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/j.1875-9114.1991.tb03592.x","volume":"11","author":"JJ Schentag","year":"1991","unstructured":"Schentag JJ. Cefmetazole sodium: pharmacology, pharmacokinetics, and clinical trials. Pharmacotherapy. 1991;11(1):2\u201319. https:\/\/doi.org\/10.1002\/j.1875-9114.1991.tb03592.x. Pubmed:2020609.","journal-title":"Pharmacotherapy"},{"issue":"4","key":"4130_CR6","doi-asserted-by":"publisher","first-page":"466","DOI":"10.7164\/antibiotics.38.466","volume":"38","author":"T Tsuji","year":"1985","unstructured":"Tsuji T, Satoh H, Narisada M, Hamashima Y, Yoshida T. Synthesis and antibacterial activity of 6315-S, a new member of the oxacephem antibiotic. J Antibiot (Tokyo). 1985;38(4):466\u201376. https:\/\/doi.org\/10.7164\/antibiotics.38.466. Pubmed:4008339.","journal-title":"J Antibiot (Tokyo)"},{"issue":"Suppl 5","key":"4130_CR7","doi-asserted-by":"publisher","first-page":"S253","DOI":"10.1007\/BF01645536","volume":"19","author":"M Ito","year":"1991","unstructured":"Ito M, Ishigami T. The meaning of the development of flomoxef and clinical experience in Japan. Infection. 1991;19(Suppl 5):S253\u20137. https:\/\/doi.org\/10.1007\/BF01645536. Pubmed:1783441.","journal-title":"Infection"},{"key":"4130_CR8","unstructured":"World Health Organization. Application for the inclusion of flomoxef sodium on the WHO Model List of Essential Medicines (EML) and Model List of Essential Medicines for Children (EMLc). Geneva: World Health Organization; 2023. Available from: https:\/\/cdn.who.int\/media\/docs\/default-source\/essential-medicines\/2023-eml-expert-committee\/applications-for-addition-of-new-medicines\/a17_flomoxef-sodium.pdf?sfvrsn=9f6f1aeb_1."},{"issue":"4","key":"4130_CR9","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1128\/CMR.18.4.657-686.2005","volume":"18","author":"DL Paterson","year":"2005","unstructured":"Paterson DL, Bonomo RA. Extended-spectrum \u03b2-lactamases: A clinical update. Clin Microbiol Rev. 2005;18(4):657\u201386. https:\/\/doi.org\/10.1128\/CMR.18.4.657-686.2005. Pubmed:16223952.","journal-title":"Clin Microbiol Rev"},{"issue":"4","key":"4130_CR10","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.diagmicrobio.2015.12.001","volume":"84","author":"Y Matsumura","year":"2016","unstructured":"Matsumura Y, Yamamoto M, Nagao M, Tanaka M, Takakura S, Ichiyama S. In vitro activities and detection performances of cefmetazole and flomoxef for extended-spectrum \u03b2-lactamase and plasmid-mediated AmpC \u03b2-lactamase-producing Enterobacteriaceae. Diagn Microbiol Infect Dis. 2016;84(4):322\u20137. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2015.12.001. Pubmed:26782634.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"5","key":"4130_CR11","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.ijantimicag.2014.11.012","volume":"45","author":"Q Yang","year":"2015","unstructured":"Yang Q, Zhang H, Cheng J, Xu Z, Xu Y, Cao B, et al. In vitro activity of flomoxef and comparators against Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis producing extended-spectrum \u03b2-lactamases in China. Int J Antimicrob Agents. 2015;45(5):485\u201390. https:\/\/doi.org\/10.1016\/j.ijantimicag.2014.11.012. Pubmed:25600890.","journal-title":"Int J Antimicrob Agents"},{"issue":"10","key":"4130_CR12","doi-asserted-by":"publisher","first-page":"e0051023","DOI":"10.1128\/aac.00510-23","volume":"67","author":"K Hayakawa","year":"2023","unstructured":"Hayakawa K, Matsumura Y, Uemura K, Tsuzuki S, Sakurai A, Tanizaki R, et al. Effectiveness of cefmetazole versus meropenem for invasive urinary tract infections caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli. Antimicrob Agents Chemother. 2023;67(10):e0051023. https:\/\/doi.org\/10.1128\/aac.00510-23. Pubmed:37702483.","journal-title":"Antimicrob Agents Chemother"},{"key":"4130_CR13","doi-asserted-by":"publisher","unstructured":"Kashihara E, Sada RM, Tsugihashi Y, Obayashi H, Nakamura A, Abe N, et al. Efficacy and safety of cefmetazole for bacteremia caused by extended-spectrum \u03b2-lactamase-producing Enterobacterales vs carbapenems: A retrospective study. Open Forum Infect Dis. 2023;10(10):ofad502. https:\/\/doi.org\/10.1093\/ofid\/ofad502.","DOI":"10.1093\/ofid\/ofad502"},{"issue":"4","key":"4130_CR14","first-page":"348","volume":"46","author":"K Iio","year":"2024","unstructured":"Iio K, Hagiya H, Higashionna T, Otsuka F. In vitro Activity of Cefmetazole and Flomoxef among Extended-Spectrum Beta-Lactamase producing Enterobacterales. New Microbiol. 2024;46(4):348\u201353.","journal-title":"New Microbiol"},{"issue":"8","key":"4130_CR15","doi-asserted-by":"publisher","first-page":"e0202276","DOI":"10.1371\/journal.pone.0202276","volume":"13","author":"Y Komatsu","year":"2018","unstructured":"Komatsu Y, Kasahara K, Inoue T, Lee ST, Muratani T, Yano H, Kirita T, Mikasa K. Molecular epidemiology and clinical features of extended-spectrum beta-lactamase- or carbapenemase-producing Escherichia coli bacteremia in Japan. PLoS ONE. 2018;13(8):e0202276. https:\/\/doi.org\/10.1371\/journal.pone.0202276.","journal-title":"PLoS ONE"},{"key":"4130_CR16","unstructured":"Boston Consulting Group, Wellcome Trust. Understanding the antibiotic manufacturing ecosystem: a view of global supply chains, pressure points, and implications for antimicrobial resistance response. 2022. Available from: https:\/\/cms.wellcome.org\/sites\/default\/files\/2022-04\/understanding-the-antibiotic-manufacturing-ecosystem-2022.pdf."},{"issue":"3","key":"4130_CR17","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jiph.2023.01.021","volume":"16","author":"H Nagano","year":"2023","unstructured":"Nagano H, Shin JH, Kunisawa S, Fushimi K, Nagao M, Imanaka Y. Impact of the cefazolin shortage on the selection and cost of parenteral antibiotics during the supply disruption period in Japan: a controlled interrupted time series analysis. J Infect Public Health. 2023;16(3):467\u201373. https:\/\/doi.org\/10.1016\/j.jiph.2023.01.021. Pubmed:36738690.","journal-title":"J Infect Public Health"},{"issue":"2","key":"4130_CR18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.7883\/yoken.JJID.2020.499","volume":"74","author":"T Kajihara","year":"2021","unstructured":"Kajihara T, Yahara K, Hirabayashi A, Shibayama K, Sugai M. Japan Nosocomial Infections Surveillance (JANIS): current status, international collaboration, and future directions for a comprehensive antimicrobial resistance surveillance system. Jpn J Infect Dis. 2021;74(2):87\u201396. https:\/\/doi.org\/10.7883\/yoken.JJID.2020.499.","journal-title":"Jpn J Infect Dis"},{"key":"4130_CR19","unstructured":"Ministry of Health, Labour and Welfare. Orientation Session for the Submission and Utilization of Data in the Japan Nosocomial Infections Surveillance (JANIS) Program 2017. Tokyo: Japan Nosocomial Infections Surveillance (JANIS); 2017. Available from: https:\/\/janis.mhlw.go.jp\/participation\/material\/2017_janis_briefing_slide.pdf."},{"issue":"10","key":"4130_CR20","doi-asserted-by":"publisher","first-page":"e1701881","DOI":"10.1126\/sciadv.1701881","volume":"3","author":"M Cokol","year":"2017","unstructured":"Cokol M, Kuru N, Bicak E, Larkins-Ford J, Aldridge BB. Efficient measurement and factorization of high-order drug interactions in Mycobacterium tuberculosis. Sci Adv. 2017;3(10):e1701881. https:\/\/doi.org\/10.1126\/sciadv.1701881. Pubmed:29026882.","journal-title":"Sci Adv"},{"key":"4130_CR21","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/978-1-0716-1460-0_30","volume":"2314","author":"N Van","year":"2021","unstructured":"Van N, Degefu YN, Aldridge BB. Efficient measurement of drug interactions with DiaMOND (Diagonal Measurement of N-Way Drug Interactions). Methods Mol Biol. 2021;2314:703\u201313. https:\/\/doi.org\/10.1007\/978-1-0716-1460-0_30. Pubmed:34235676.","journal-title":"Methods Mol Biol"},{"issue":"3","key":"4130_CR22","doi-asserted-by":"publisher","first-page":"e0506922","DOI":"10.1128\/spectrum.05069-22","volume":"11","author":"H Hirakawa","year":"2023","unstructured":"Hirakawa H, Takita A, Sato Y, Hiramoto S, Hashimoto Y, Ohshima N, et al. Inactivation of ackA and pta genes reduces GlpT expression and susceptibility to fosfomycin in Escherichia coli. Microbiol Spectr. 2023;11(3):e0506922. https:\/\/doi.org\/10.1128\/spectrum.05069-22. Pubmed:37199605.","journal-title":"Microbiol Spectr"},{"key":"4130_CR23","doi-asserted-by":"crossref","unstructured":"Yasunaga H. In: Real world data in Japan: Chapter II. The diagnosis procedure combination database. Ann Clin Epidemiol. 2019;1:76\u20139.","DOI":"10.37737\/ace.1.3_76"},{"issue":"7","key":"4130_CR24","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.3390\/nu13072343","volume":"13","author":"M Shiozawa","year":"2021","unstructured":"Shiozawa M, Kaneko H, Itoh H, Morita K, Okada A, Matsuoka S, et al. Association of body mass index with ischemic and hemorrhagic stroke. Nutrients. 2021;13(7):2343. https:\/\/doi.org\/10.3390\/nu13072343. Pubmed:34371853.","journal-title":"Nutrients"},{"issue":"4","key":"4130_CR25","doi-asserted-by":"publisher","first-page":"e002736","DOI":"10.1136\/bmjopen-2013-002736","volume":"3","author":"K Shigematsu","year":"2013","unstructured":"Shigematsu K, Nakano H, Watanabe Y. The eye response test alone is sufficient to predict stroke outcome\u2014reintroduction of Japan Coma Scale: a cohort study. BMJ Open. 2013;3(4):e002736. https:\/\/doi.org\/10.1136\/bmjopen-2013-002736. Pubmed:23633419.","journal-title":"BMJ Open"},{"issue":"10","key":"4130_CR26","doi-asserted-by":"publisher","first-page":"531","DOI":"10.2188\/jea.JE20220147","volume":"33","author":"M Nakajima","year":"2023","unstructured":"Nakajima M, Okada Y, Sonoo T, Goto T. Development and validation of a novel method for converting the Japan Coma Scale to Glasgow Coma Scale. J Epidemiol. 2023;33(10):531\u20135. https:\/\/doi.org\/10.2188\/jea.JE20220147. Pubmed:35851565.","journal-title":"J Epidemiol"},{"issue":"11","key":"4130_CR27","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130\u20139. https:\/\/doi.org\/10.1097\/01.mlr.0000182534.19832.83. Pubmed:16224307.","journal-title":"Med Care"},{"issue":"1","key":"4130_CR28","doi-asserted-by":"publisher","first-page":"9785","DOI":"10.1038\/s41598-025-90762-1","volume":"15","author":"YM Wi","year":"2025","unstructured":"Wi YM, Choi JY, Lee DE, Jun SH, Kwon KT, Ko KS. Antimicrobial activity of cephamycins and \u03b2-lactam\/\u03b2-lactamase inhibitors against ESBL-producing Escherichia coli and Klebsiella pneumoniae under standard and high bacterial inocula. Sci Rep. 2025;15(1):9785. https:\/\/doi.org\/10.1038\/s41598-025-90762-1.","journal-title":"Sci Rep"},{"issue":"9","key":"4130_CR29","doi-asserted-by":"publisher","first-page":"5107","DOI":"10.1128\/AAC.00701-15","volume":"59","author":"Y Matsumura","year":"2015","unstructured":"Matsumura Y, Yamamoto M, Nagao M, Komori T, Fujita N, Hayashi A, et al. Multicenter retrospective study of cefmetazole and flomoxef for treatment of extended-spectrum-\u03b2-lactamase-producing Escherichia coli bacteremia. Antimicrob Agents Chemother. 2015;59(9):5107\u201313. https:\/\/doi.org\/10.1128\/AAC.00701-15.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"4130_CR30","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1093\/cid\/cix034","volume":"64","author":"PD Tamma","year":"2017","unstructured":"Tamma PD, Rodriguez-Bano J. The use of noncarbapenem \u03b2-lactams for the treatment of extended-spectrum \u03b2-lactamase infections. Clin Infect Dis. 2017;64(7):972\u201380. https:\/\/doi.org\/10.1093\/cid\/cix034. Pubmed:28362938.","journal-title":"Clin Infect Dis"},{"key":"4130_CR31","unstructured":"Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 30th ed. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2023."},{"issue":"9","key":"4130_CR32","doi-asserted-by":"publisher","first-page":"e0025823","DOI":"10.1128\/aac.00258-23","volume":"67","author":"H Yamashiro","year":"2023","unstructured":"Yamashiro H, Kasamatsu Y, Anan N, Takemura M, Yamano Y. In vitro efficacy of humanized regimen of flomoxef against extended-spectrum \u03b2-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Antimicrob Agents Chemother. 2023;67(9):e0025823. https:\/\/doi.org\/10.1128\/aac.00258-23.","journal-title":"Antimicrob Agents Chemother"},{"key":"4130_CR33","unstructured":"JMDC Inc. JMDC real world. Available from: https:\/\/www.phm-jmdc.com\/."},{"issue":"5","key":"4130_CR34","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nrmicro3432","volume":"13","author":"AL Flores-Mireles","year":"2015","unstructured":"Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015;13(5):269\u201384. https:\/\/doi.org\/10.1038\/nrmicro3432. Pubmed:25853778.","journal-title":"Nat Rev Microbiol"},{"issue":"4","key":"4130_CR35","doi-asserted-by":"publisher","first-page":"623","DOI":"10.3390\/pathogens12040623","volume":"12","author":"G Mancuso","year":"2023","unstructured":"Mancuso G, Midiri A, Gerace E, Marra M, Zummo S, Biondo C. Urinary tract infections: the current scenario and future prospects. Pathogens. 2023;12(4):623. https:\/\/doi.org\/10.3390\/pathogens12040623.","journal-title":"Pathogens"},{"issue":"4","key":"4130_CR36","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s00467-016-3394-5","volume":"32","author":"E Joyce","year":"2017","unstructured":"Joyce E, Glasner P, Ranganathan S, Swiatecka-Urban A. Tubulointerstitial nephritis: diagnosis, treatment, and monitoring. Pediatr Nephrol. 2017;32(4):577\u201387.","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"4130_CR37","doi-asserted-by":"publisher","first-page":"3947","DOI":"10.1038\/s41467-024-48296-z","volume":"15","author":"B Kakaraskoska Boceska","year":"2024","unstructured":"Kakaraskoska Boceska B, Vilken T, Xavier BB, Kostyanev T, Lin Q, Lammens C, et al. Assessment of three antibiotic combination regimens against Gram-negative bacteria causing neonatal sepsis in low- and middle-income countries. Nat Commun. 2024;15(1):3947. https:\/\/doi.org\/10.1038\/s41467-024-48296-z. Pubmed:38729951.","journal-title":"Nat Commun"},{"issue":"3","key":"4130_CR38","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1093\/jac\/dkab468","volume":"77","author":"CA Darlow","year":"2021","unstructured":"Darlow CA, Hope W. Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales. J Antimicrob Chemother. 2021;77(3):711\u20138.","journal-title":"J Antimicrob Chemother"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04130-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-025-04130-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04130-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T10:47:25Z","timestamp":1751366845000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-025-04130-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4130"],"URL":"https:\/\/doi.org\/10.1186\/s12916-025-04130-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.07.16.24310469","asserted-by":"object"}]},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"10 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This part of the study was approved by the Ethics Committee of Tokushima University Hospital (protocol number: 4492).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"396"}}